TW202112394A - 以肽核酸為基礎之佐劑 - Google Patents

以肽核酸為基礎之佐劑 Download PDF

Info

Publication number
TW202112394A
TW202112394A TW109119031A TW109119031A TW202112394A TW 202112394 A TW202112394 A TW 202112394A TW 109119031 A TW109119031 A TW 109119031A TW 109119031 A TW109119031 A TW 109119031A TW 202112394 A TW202112394 A TW 202112394A
Authority
TW
Taiwan
Prior art keywords
adjuvant
peptide
nucleic acid
administration
cell
Prior art date
Application number
TW109119031A
Other languages
English (en)
Chinese (zh)
Inventor
三股亮大郎
神田明日美
Original Assignee
日商電化股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商電化股份有限公司 filed Critical 日商電化股份有限公司
Publication of TW202112394A publication Critical patent/TW202112394A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109119031A 2019-06-06 2020-06-05 以肽核酸為基礎之佐劑 TW202112394A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019106444 2019-06-06
JP2019-106444 2019-06-06

Publications (1)

Publication Number Publication Date
TW202112394A true TW202112394A (zh) 2021-04-01

Family

ID=73652763

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109119031A TW202112394A (zh) 2019-06-06 2020-06-05 以肽核酸為基礎之佐劑

Country Status (8)

Country Link
US (1) US12016920B2 (https=)
EP (1) EP3981426A4 (https=)
JP (1) JP7602457B2 (https=)
KR (1) KR20220017919A (https=)
CN (1) CN113939313B (https=)
AU (1) AU2020288030A1 (https=)
TW (1) TW202112394A (https=)
WO (1) WO2020246584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157429A (ko) 2021-04-07 2023-11-16 덴카 주식회사 애주번트 활성 증강제 및 애주번트 조성물
JP2023128573A (ja) * 2022-03-03 2023-09-14 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
ITMI20030860A1 (it) * 2003-04-29 2004-10-30 Univ Bologna Metodo per l'inibizione selettiva del gene n-myc
ZA200707967B (en) 2005-04-08 2008-11-26 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2009126933A2 (en) * 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US9562228B2 (en) * 2012-09-14 2017-02-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of MYC by double-stranded RNA
MX374090B (es) * 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US20160206715A1 (en) 2013-03-15 2016-07-21 Bullet Biotechnology, Inc. Specific multivalent virus-like particle vaccines and uses thereof
US9902973B2 (en) * 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
WO2018013924A1 (en) * 2016-07-15 2018-01-18 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds

Also Published As

Publication number Publication date
JP7602457B2 (ja) 2024-12-18
WO2020246584A1 (ja) 2020-12-10
AU2020288030A1 (en) 2022-01-06
KR20220017919A (ko) 2022-02-14
EP3981426A1 (en) 2022-04-13
EP3981426A4 (en) 2023-06-07
CN113939313B (zh) 2024-11-01
JPWO2020246584A1 (https=) 2020-12-10
US12016920B2 (en) 2024-06-25
CN113939313A (zh) 2022-01-14
US20230330221A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2010536878A (ja) インフルエンザタンパク質を製造および使用する組成物および方法
JP2010105968A (ja) カチオン性ナノゲルを用いる粘膜ワクチン
JP2009530264A (ja) Ｃｄ１ｄリガンドを使用する免疫化のための組成物および方法
JP7602457B2 (ja) ペプチド核酸を基盤としたアジュバント
US9198965B2 (en) Peptide adjuvant for influenza vaccination
US20230270843A1 (en) Post-Exposure Vaccination Against Viral Respiratory Infections
JP2023539713A (ja) ワクチン組成物、それらの方法、および使用
JP2013545735A (ja) インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン
US20240207395A1 (en) Adjuvant activity enhancer and adjuvant composition
JP2025528166A (ja) 狂犬病ｇタンパク質及びその使用
JP2024545833A (ja) コロナウイルス科ウイルスによる感染症の処置または予防のためのウイルス様粒子
KR20240011134A (ko) Rsv 및 piv3 감염을 예방하기 위한 조성물 및 방법
KR20230157397A (ko) 인플루엔자 백신
EP4225366A1 (en) Imdq-peg-chol adjuvant and uses thereof
KR20210068429A (ko) 점막 애주번트
KR20230157398A (ko) 경비 투여 인플루엔자 백신
CN104936616A (zh) 针对登革病毒的疫苗组合物
CA3172479A1 (en) Haptenized coronavirus spike proteins
HK1128077B (en) Intranasal influenza vaccine based on virosomes
HK1128077A1 (en) Intranasal influenza vaccine based on virosomes